Clinical trialNCT05830097UnknownPhase 1/PHASE2Interventional

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

SponsorCoherent Biopharma (Hefei) Co., Ltd.Enrollment260Cancer ColorectalCancer of EsophagusCancer of PancreasCancer, BreastCancer, Lung

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Lin Shen, MD
Peking University Cancer Hospital & Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China

Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Recruiting

United States

Toi Clinical Research Llc
Cerritos, California, United States
Recruiting
Florida Cancer Specialists & Research Institute
Orlando, Florida, United States
Recruiting
Northwell Health Inc.
Manhasset, New York, United States
Recruiting
Next Oncology
Fairfax, Virginia, United States
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CBP-1019

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Mar 2023
Primary completion: 30 Jun 2025
Completion: 30 Sept 2025
Last update posted: 26 Aug 2024
Registered enrollment: 260
Registry id: NCT05830097

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.